For all investors who are interested, there has been a stream of positive news since February 2009.
www.pharmagap.com
USA - OTC.BB: PHRGF International / Canada - TSX.V: GAP
...... the big news in 2009 is that the National Cancer Institute in Maryland, USA, is in the process of a 60 human cancer cell line validation test with PharmaGap’s lead drug PhG-alpha-1, for breast and bowel cancer, which has been 80% successful with reducing or killing cancer cells in animal studies (2008).
If the US National Cancer Institute gives PharmaGap its blessings the share price should appreciate considerably.
PharmaGap Provides Guidance on Timing of Testing at National Cancer Institute
Ottawa, Ontario/May 7, 2009 – PharmaGap Inc. (TSX-V: GAP / OTC.BB-PHRGF) (“PharmaGap” or “the Company”) today announced that the National Cancer Institute (“NCI”) has confirmed receipt of PharmaGap’s drug product PhG-alpha-1 at its drug depository in Rockville, MD, in advance of testing in the NCI’s tumour cell panel consisting of 60 human cancer cell lines. The NCI has advised the Company that the results of the initial single dose test could normally be expected in a minimum of six to ten weeks.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP / OTC.BB-PHGRF), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development and targets PKC alpha. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage.
For more information on PharmaGap please visit the Company's website at www.pharmagap.com.
Good tips. Penny stocks are most closely associated with pump and dump schemes, where stocks are brought in bulk by stock speculators and a massive campaign to promote the stock starts, jacking up the price of the stock.